Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 332

1.

Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?

Af Hällström TM, Puhka M, Kallioniemi O.

EMBO Mol Med. 2015 Jun 1. pii: e201505332. doi: 10.15252/emmm.201505332. [Epub ahead of print] No abstract available.

2.

The impact of low-frequency and rare variants on lipid levels.

Surakka I, Horikoshi M, Mägi R, Sarin AP, Mahajan A, Lagou V, Marullo L, Ferreira T, Miraglio B, Timonen S, Kettunen J, Pirinen M, Karjalainen J, Thorleifsson G, Hägg S, Hottenga JJ, Isaacs A, Ladenvall C, Beekman M, Esko T, Ried JS, Nelson CP, Willenborg C, Gustafsson S, Westra HJ, Blades M, de Craen AJ, de Geus EJ, Deelen J, Grallert H, Hamsten A, Havulinna AS, Hengstenberg C, Houwing-Duistermaat JJ, Hyppönen E, Karssen LC, Lehtimäki T, Lyssenko V, Magnusson PK, Mihailov E, Müller-Nurasyid M, Mpindi JP, Pedersen NL, Penninx BW, Perola M, Pers TH, Peters A, Rung J, Smit JH, Steinthorsdottir V, Tobin MD, Tsernikova N, van Leeuwen EM, Viikari JS, Willems SM, Willemsen G, Schunkert H, Erdmann J, Samani NJ, Kaprio J, Lind L, Gieger C, Metspalu A, Slagboom PE, Groop L, van Duijn CM, Eriksson JG, Jula A, Salomaa V, Boomsma DI, Power C, Raitakari OT, Ingelsson E, Järvelin MR, Thorsteinsdottir U, Franke L, Ikonen E, Kallioniemi O, Pietiäinen V, Lindgren CM, Stefansson K, Palotie A, McCarthy MI, Morris AP, Prokopenko I, Ripatti S; ENGAGE Consortium.

Nat Genet. 2015 Jun;47(6):589-97. doi: 10.1038/ng.3300. Epub 2015 May 11.

PMID:
25961943
3.

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K.

Blood Cancer J. 2015 May 1;5:e309. doi: 10.1038/bcj.2015.30.

4.

MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.

Aakula A, Leivonen SK, Hintsanen P, Aittokallio T, Ceder Y, Børresen-Dale AL, Perälä M, Östling P, Kallioniemi O.

Mol Oncol. 2015 Mar 21. pii: S1574-7891(15)00050-2. doi: 10.1016/j.molonc.2015.03.001. [Epub ahead of print]

PMID:
25907805
5.

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW, Wennerberg K.

Nature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.

PMID:
25686603
6.

miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen.

Larne O, Östling P, Haflidadóttir BS, Hagman Z, Aakula A, Kohonen P, Kallioniemi O, Edsjö A, Bjartell A, Lilja H, Lundwall Å, Ceder Y.

Eur Urol. 2014 Dec 30. pii: S0302-2838(14)01280-9. doi: 10.1016/j.eururo.2014.12.025. [Epub ahead of print]

PMID:
25556023
7.

Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.

Saeed K, Östling P, Björkman M, Mirtti T, Alanen K, Vesterinen T, Sankila A, Lundin J, Lundin M, Rannikko A, Nordling S, Mpindi JP, Kohonen P, Iljin K, Kallioniemi O, Rantala JK.

Int J Cancer. 2015 Jun 1;136(11):2535-45. doi: 10.1002/ijc.29303. Epub 2014 Nov 20.

PMID:
25359680
8.

Genetic Instability of Influenza pH1N1 Viruses.

Jalovaara P, Bychkov D, Ahtiainen L, Kallio-Kokko H, Valkonen M, Kantele A, Mattila P, Almusa H, Kallioniemi O, Kainov D.

Genome Announc. 2014 Oct 2;2(5). pii: e00841-14. doi: 10.1128/genomeA.00841-14.

9.

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis.

Khan SA, Virtanen S, Kallioniemi OP, Wennerberg K, Poso A, Kaski S.

Bioinformatics. 2014 Sep 1;30(17):i497-504. doi: 10.1093/bioinformatics/btu456.

10.

Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization.

Ammad-ud-din M, Georgii E, Gönen M, Laitinen T, Kallioniemi O, Wennerberg K, Poso A, Kaski S.

J Chem Inf Model. 2014 Aug 25;54(8):2347-59. doi: 10.1021/ci500152b. Epub 2014 Aug 6.

PMID:
25046554
11.

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio T.

Sci Rep. 2014 Jun 5;4:5193. doi: 10.1038/srep05193.

12.

Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer.

Christensen LL, Holm A, Rantala J, Kallioniemi O, Rasmussen MH, Ostenfeld MS, Dagnaes-Hansen F, Øster B, Schepeler T, Tobiasen H, Thorsen K, Sieber OM, Gibbs P, Lamy P, Hansen TF, Jakobsen A, Riising EM, Helin K, Lubinski J, Hagemann-Madsen R, Laurberg S, Ørntoft TF, Andersen CL.

PLoS One. 2014 Jun 3;9(6):e96767. doi: 10.1371/journal.pone.0096767. eCollection 2014.

13.

A community effort to assess and improve drug sensitivity prediction algorithms.

Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G.

Nat Biotechnol. 2014 Dec;32(12):1202-12. doi: 10.1038/nbt.2877. Epub 2014 Jun 1.

PMID:
24880487
14.

Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.

Denisova OV, Söderholm S, Virtanen S, Von Schantz C, Bychkov D, Vashchinkina E, Desloovere J, Tynell J, Ikonen N, Theisen LL, Nyman TA, Matikainen S, Kallioniemi O, Julkunen I, Muller CP, Saelens X, Verkhusha VV, Kainov DE.

Antimicrob Agents Chemother. 2014 Jul;58(7):3689-96. doi: 10.1128/AAC.02798-13. Epub 2014 Apr 21.

15.

A novel transcript, VNN1-AB, as a biomarker for colorectal cancer.

Løvf M, Nome T, Bruun J, Eknaes M, Bakken AC, Mpindi JP, Kilpinen S, Rognum TO, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI.

Int J Cancer. 2014 Nov 1;135(9):2077-84. doi: 10.1002/ijc.28855. Epub 2014 Mar 29.

PMID:
24687856
16.

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA.

Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27. No abstract available.

PMID:
24573384
17.

Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.

Pavet V, Shlyakhtina Y, He T, Ceschin DG, Kohonen P, Perälä M, Kallioniemi O, Gronemeyer H.

Cell Death Dis. 2014 Jan 30;5:e1043. doi: 10.1038/cddis.2014.5.

18.

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation.

Andersson EI, Rajala HL, Eldfors S, Ellonen P, Olson T, Jerez A, Clemente MJ, Kallioniemi O, Porkka K, Heckman C, Loughran TP Jr, Maciejewski JP, Mustjoki S.

Blood Cancer J. 2013 Dec 6;3:e168. doi: 10.1038/bcj.2013.65.

19.

Break-induced replication repair of damaged forks induces genomic duplications in human cells.

Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov E, Helleday T, Haber JE, Iliakis G, Kallioniemi OP, Halazonetis TD.

Science. 2014 Jan 3;343(6166):88-91. doi: 10.1126/science.1243211. Epub 2013 Dec 5.

20.

High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.

Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M.

PLoS One. 2013 Oct 23;8(10):e77232. doi: 10.1371/journal.pone.0077232. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk